Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Molecular MRD detection in AML

Peter Valk • 14 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia

In this video Peter Valk, PhD, from the Erasmus University Medical Center, Rotterdam, Netherlands, discusses precision medicine in acute myeloid leukemia (AML), namely biomarkers for early detection and molecular measurable residual disease detection. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Peter Valk

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA
1:13
Molecular MRD as a prognostic marker for AML patients with mutated CEBPA
Peter Valk • 4 Sep 2024
Introducing molecular diagnostics to improve leukemia care in developing countries
2:06
Introducing molecular diagnostics to improve leukemia care in developing countries
Peter Valk • 4 Sep 2024
Future considerations for MRD in AML
1:03
Future considerations for MRD in AML
Peter Valk • 29 Sep 2022
Distinguishing between de novo AML and secondary AML using mutational signatures
2:20
Distinguishing between de novo AML and secondary AML using mutational signatures
Peter Valk • 29 Sep 2022

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Peter Valk • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Peter Valk • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Peter Valk • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Peter Valk • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals